Zyversa Therapeutics Inc
(ZVSA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 120 | 2,034 | 3,138 | 1,579 | 229 |
| TOTAL | $641 | $2,900 | $3,353 | $2,005 | $1,116 |
| Non-Current Assets | |||||
| PPE Net | 2 | 4 | 7 | 10 | 12 |
| Intangibles | 18,648 | 18,648 | 18,648 | 30,806 | 30,806 |
| Other Non-Current Assets | 179 | 99 | 106 | 31 | 54 |
| TOTAL | $18,828 | $18,751 | $18,761 | $30,847 | $30,872 |
| Total Assets | $19,470 | $21,651 | $22,114 | $32,852 | $31,988 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,317 | 8,128 | 8,432 | 8,898 | 8,144 |
| Accrued Expenses | 1,678 | 1,455 | 1,755 | 2,776 | 2,281 |
| TOTAL | $9,995 | $9,583 | $10,195 | $11,707 | $10,485 |
| Non-Current Liabilities | |||||
| TOTAL | $855 | $845 | $845 | $1,441 | $1,442 |
| Total Liabilities | $10,850 | $10,428 | $11,040 | $13,148 | $11,926 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,029 | 835 | 759 | 124 | 88 |
| Common Shares | 0 | 0 | 0 | 4 | 2 |
| Retained earnings | -108,810 | -106,046 | -103,219 | -89,881 | -86,978 |
| Other shareholders' equity | -7 | -7 | -7 | -7 | -7 |
| TOTAL | $8,620 | $11,223 | $11,075 | $19,704 | $20,062 |
| Total Liabilities And Equity | $19,470 | $21,651 | $22,114 | $32,852 | $31,988 |